We are live on ! Find out more
OKYO

OKYO Pharma

10 hedge funds and large institutions have $1.15M invested in OKYO Pharma in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 810 (+2)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

5.07% less ownership

Funds ownership: 6.84%1.77% (-5.1%)

78% less capital invested

Capital invested by funds: $5.14M → $1.15M (-$3.99M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
4
Increased
1
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
DIG
1
Dauntless Investment Group
New Hampshire
$746K -$4.23M -1,950,525 -81%
Renaissance Technologies
2
Renaissance Technologies
New York
$286K +$210K +96,800 +235%
XT
3
XTX Topco
Cayman Islands
$36.5K +$38.2K +17,612 New
Cerity Partners
4
Cerity Partners
New York
$26.5K
Geode Capital Management
5
Geode Capital Management
Massachusetts
$25K
Wealth Enhancement Advisory Services
6
Wealth Enhancement Advisory Services
Minnesota
$21.2K
UBS Group
7
UBS Group
Switzerland
$4.5K +$4.71K +2,172 New
EI
8
EFG International
$1.91K +$2K +923 New
Osaic Holdings
9
Osaic Holdings
Arizona
$314
Morgan Stanley
10
Morgan Stanley
New York
$21 +$22 +10 New
Northern Trust
11
Northern Trust
Illinois
-$114K -57,158 Closed
Citadel Advisors
12
Citadel Advisors
Florida
-$30.7K -15,355 Closed

OKYO Hedge Fund Activity: Q4 2025 in Review

10 of the 8,232 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q4 2025, worth a combined $1.15M — down 78% from $5.14M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new OKYO positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $210K. The largest seller was Dauntless Investment Group, cutting an estimated $4.23M.

  • 10 institutional investors held OKYO Pharma (OKYO) as of Q4 2025, up from 8 in Q3 2025.
  • Funds reported $1.15M of OKYO Pharma stock for Q4 2025, down 78% quarter-over-quarter.
  • 4 funds opened new OKYO Pharma positions in Q4 2025 and 2 closed out, a net change of +2 holders.
  • The largest OKYO Pharma buyer in Q4 2025 was Renaissance Technologies, an estimated $210K added.
  • The largest OKYO Pharma seller in Q4 2025 was Dauntless Investment Group, an estimated $4.23M sold.

Based on aggregated 13F filings for Q4 2025.